Pharmaceutical companies, on account of price pressures and an intense regulatory gaze, are investing in data analytics and digital tools to sharpen their marketing focus and improve compliance.
The move comes in the backdrop of price competitiveness in key markets and regulatory actions leading to adverse audit observations and warning letters.
“Businesses that digitalise will have a huge competitive advantage over others. At Cipla we are leveraging new-age technologies to drive efficiencies,” said Kedar Upadhye, Cipla's global chief financial officer.
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.
Subscribe To Insights
Key stories on business-standard.com are available to premium subscribers only.Already a BS Premium subscriber? Log in NOW
Or
Also Read
Cipla
- NSE
- BSE
- 1D
- 5D
- 1M
- 3M
- 6M
- 5Y
- MAX